Contents
[hide]
[show]

Mucolipidosis type IV, also known as ML IV, is a rare genetic disorder that impairs the body’s ability to process certain fats and proteins. It is caused by mutations in the Mucolipin-1 gene (MCOLN1), which is responsible for the production of a protein called mucolipin-1.

Individuals with ML IV typically experience delayed development and intellectual disability. The signs and symptoms of ML IV can vary from person to person, but usually first appear during early infancy. In addition to these typical features, ML IV is also associated with other health problems, including vision impairment, muscle weakness, and respiratory difficulties.

ML IV is an autosomal recessive disorder, meaning that both parents must carry a copy of the mutated gene in order for their child to be affected. ML IV occurs in approximately 1 in 40,000 to 1 in 120,000 individuals, with a higher frequency observed in the Ashkenazi Jewish and Puerto Rican populations.

There is currently no cure for ML IV, but there are resources and support available for patients and families affected by this condition. Research articles, clinical trials, and genetic testing information can be found on websites such as PubMed, OMIM, ClinicalTrials.gov, and the Mucolipidosis Type IV Foundation. These resources provide valuable information for those who want to learn more about ML IV and stay up-to-date with the latest scientific advancements.

Advocacy organizations like the Mucolipidosis Type IV Foundation and the National Organization for Rare Disorders (NORD) also provide support, education, and advocacy for individuals affected by ML IV and their families. These organizations offer resources, connect patients with clinical trials and studies, and provide a network for sharing experiences and information.

Frequency

Mucolipidosis type IV is a rare genetic condition that affects multiple body systems. It is estimated to occur in approximately 1 in 40,000 to 1 in 100,000 individuals worldwide. The condition is more common in individuals of Ashkenazi Jewish descent, with a reported frequency of 1 in 1,200 to 1 in 4,000 individuals in this population.

The average length of the portion of a doctor appointment in which the patient actually sees the doctor is up from previous years, rising by about 12 seconds per year, according to Reuters. However, 60% of physicians report dissatisfaction with the amount of time they spend with their patients, athenaInsight Many doctors now spend more time on paperwork than seeing patients, and a primary care physician who spends 5 minutes of face-to-face time with a patient will spend another 19.3 minutes, on average, working on that patient’s electronic health records (EHRs).

Mucolipidosis type IV is caused by mutations in the MCOLN1 gene, which provides instructions for making the mucolipin-1 protein. This protein is involved in the transport of certain substances within cells. When the mucolipin-1 protein is impaired or absent, these substances accumulate in the lysosomes, which are cellular structures involved in the breakdown of waste materials.

The signs and symptoms of mucolipidosis type IV can vary widely from patient to patient, even among siblings with the same genetic mutation. Some individuals may exhibit symptoms such as delayed development and motor skills, cognitive impairment, vision and hearing problems, and skeletal abnormalities.

Diagnosis for mucolipidosis type IV can be confirmed through genetic testing, which can identify mutations in the MCOLN1 gene. Additional testing may also be done to assess lysosomal enzyme activity and evaluate the storage of materials in cells.

At this time, there is no cure for mucolipidosis type IV, and treatment is focused on managing the symptoms and improving quality of life. Supportive therapy may include physical and occupational therapy, specialized education, and assistive devices to aid mobility and communication.

Research and clinical trials are ongoing to learn more about the causes, genetics, and associated conditions of mucolipidosis type IV. Resources such as OMIM (Online Mendelian Inheritance in Man) and PubMed provide additional information on scientific articles and studies related to this condition. ClinicalTrials.gov also lists current clinical trials that may be available for patient participation.

Support and advocacy organizations, such as the National Mucolipidosis Association, can provide further resources, information, and support for individuals and families affected by mucolipidosis type IV.

Causes

Mucolipidosis type IV is caused by mutations in the MCOLN1 gene.

This gene provides instructions for making a protein called mucolipin-1, which is involved in the transport of molecules within cells.

Mutations in the MCOLN1 gene lead to impaired function of mucolipin-1, resulting in the accumulation of certain substances (mucolipids) within the lysosomes of cells.

This buildup of mucolipids interferes with the normal functioning of various organs and tissues.

Mucolipidosis type IV has an autosomal recessive pattern of inheritance, which means that both copies of the MCOLN1 gene in each cell must have mutations for the condition to be present.

The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Research has shown that mucolipidosis type IV is more common in certain populations, particularly among Ashkenazi Jews and individuals of Puerto Rican descent.

In the Ashkenazi Jewish population, the frequency of the condition is estimated to be about 1 in 50,000 individuals.

Additional causes of mucolipidosis type IV are still being studied, and more research is needed to fully understand the genetic and environmental factors that contribute to the development of this condition.

For more information about the causes of mucolipidosis type IV, you can visit scientific resources such as PubMed, OMIM, and the Genetic and Rare Diseases Information Center.

Learn more about the gene associated with Mucolipidosis type IV

Mucolipidosis type IV is a rare genetic condition that causes impaired lysosomal function. This condition is usually associated with mutations in the MCOLN1 gene.

See also  TMCO1 gene

The MCOLN1 gene, also known as mucolipin-1, is responsible for producing proteins that are involved in the normal function of lysosomal channels. These channels play a crucial role in transporting substances within the lysosomes.

People with Mucolipidosis type IV typically have mutations in both copies of the MCOLN1 gene, inherited in an autosomal recessive manner. The frequency of this condition varies among different populations, with a higher prevalence reported in the Ashkenazi Jewish population.

Signs and symptoms of Mucolipidosis type IV can vary widely among affected individuals. Some common features of the condition include delayed motor development, intellectual disability, and impaired vision. Additional information about the symptoms and clinical presentation of Mucolipidosis type IV can be found on OMIM: 252650.

Research and studies on Mucolipidosis type IV are ongoing, and several resources are available for both patients and healthcare providers. For more information on the MCOLN1 gene and associated diseases, you can visit the Mucolipidosis Type IV Foundation’s website: mucolipidosis.org.

Genetic testing is available for diagnosing Mucolipidosis type IV. If you suspect that you or someone you know may have this condition, it is recommended to consult with a healthcare professional for further evaluation.

Advocacy groups and support networks, such as the Mucolipidosis Type IV Foundation, can provide additional resources, scientific articles, and patient information on Mucolipidosis type IV. You can find a comprehensive list of references and scientific studies on PubMed: mucolipidosis type iv.

ClinicalTrials.gov is another valuable resource for information on current research studies and clinical trials related to Mucolipidosis type IV. You can search for relevant clinical trials using the search term “mucolipidosis type IV” on the ClinicalTrials.gov website: clinicaltrials.gov.

Learning more about the MCOLN1 gene and its association with Mucolipidosis type IV can provide a better understanding of this rare condition, and may help in the development of new treatments and interventions in the future.

Inheritance

Mucolipidosis type IV (MLIV) is an autosomal recessive genetic condition. This means that individuals with MLIV inherit two copies of a mutated gene, one from each parent. MLIV is caused by mutations in the MCOLN1 gene, which provides instructions for producing the mucolipin-1 protein. This protein is involved in the functioning of lysosomes, which are responsible for digesting and recycling cellular waste.

The impaired function of mucolipin-1 leads to the accumulation of certain substances called mucolipids within the lysosomes, causing the characteristic signs and symptoms of MLIV. The MCOLN1 gene is located on chromosome 19 and has been associated with MLIV.

MLIV is a relatively rare condition, with a typical frequency of 1 in 40,000 to 120,000 individuals. It is more common in certain populations, such as individuals of Ashkenazi Jewish descent, where the frequency can be as high as 1 in 25,000. MLIV has been identified in individuals from various ethnic backgrounds.

Testing for MLIV can be done through genetic testing, which can detect mutations in the MCOLN1 gene. Genetic counseling can provide individuals and families with more information about the inheritance pattern of MLIV and the risks of passing it on to future generations.

There are currently no specific treatments for MLIV, and management involves addressing the symptoms and complications that arise. Support and advocacy organizations, such as the ML4 Foundation, provide information and resources for individuals and families affected by MLIV.

Additional information about genetic studies and research on MLIV can be found in scientific articles and databases such as OMIM and PubMed. Clinical trials for potential treatments and interventions can be found on ClinicalTrials.gov.

Other Names for This Condition

  • Mucolipidosis type IV (ML4)
  • Mucolipidosis IV
  • MLIV
  • Mucolipidosis type 4
  • MLIV/Mucolipidosis type IV
  • Mucolipidoses type 4
  • Mucolipidoses type IV
  • Sialolipidosis
  • Tay-Sachs disease variant B
  • Cochin Jewish disorder
  • Cardiomyopathy, X-linked, and neutral lipid storage disease
  • Triglipid storage disease with impaired leukocyte acid phosphohydrolase

Other names for this condition can include variations of “Mucolipidosis type IV” or “MLIV.” This rare genetic disease is also known as “Mucolipidosis IV” or “MLIV/Mucolipidosis type IV.” It may be referred to as “Sialolipidosis” or “Tay-Sachs disease variant B” due to its clinical similarities to those conditions. “Mucolipidosis type 4” and “Mucolipidosis type 4” are alternate spellings.

Specific ethnic groups may have their own names for this condition. For example, in the Ashkenazi Jewish population, it is known as “Cochin Jewish disorder.” The condition may also be associated with “Cardiomyopathy, X-linked, and neutral lipid storage disease” or “Triglipid storage disease with impaired leukocyte acid phosphohydrolase.”

These additional names can provide more information and resources for learning about the condition, including scientific research, patient support resources, and genetic testing. They can be used to search for more articles and studies on Mucolipidosis type IV, and to find clinical trials and research studies with the condition as a focus. The frequency of the condition, associated signs and symptoms, and inheritance patterns can also be explored using these alternative names.

References and resources:

Additional Information Resources

  • The Mucolipin-1 (MCOLN1) Gene

    • Learn more about the MCOLN1 gene, which is associated with Mucolipidosis Type IV, on the Genet Online Mendelian Inheritance in Man (OMIM) catalog. This resource provides detailed information about the genetic condition, including the normal function of the MCOLN1 gene and the proteins it produces.

  • ClinicalTrials.gov

    • Find out about ongoing clinical trials for Mucolipidosis Type IV on ClinicalTrials.gov. This website provides information about studies and testing opportunities for patients with this condition. You can also learn about the frequency and inheritance patterns of mucolipidosis and other related diseases.

  • Mucolipidosis Type IV Advocacy and Support

    • For additional support and information about Mucolipidosis Type IV, visit the Mucolipidosis Type IV Foundation. This organization provides resources and articles for patients and their families, as well as access to scientific research and studies related to mucolipidosis.

  • Mucolipidosis Type IV Center

    • The Mucolipidosis Type IV Center at Puertollano University provides comprehensive information and research on this condition. You can learn about the typical signs and impaired development associated with mucolipidosis, as well as the causes and inheritance patterns of the disease.

See also  IFT140 gene

Genetic Testing Information

Genetic testing is a crucial tool in diagnosing and understanding rare genetic diseases like Mucolipidosis type IV. By analyzing an individual’s DNA, genetic testing can provide valuable information about the specific genetic mutations that cause the condition.

Testing:

  • ClinicalTrials.gov provides information on ongoing research studies and clinical trials related to Mucolipidosis type IV. These studies aim to further our understanding of the disease and develop potential treatment options.
  • Genetic testing for Mucolipidosis type IV typically involves analyzing the mcoln1 gene, which is associated with this condition.
  • Specialized genetic testing centers can provide more information on the testing process and available resources.

About Mucolipidosis type IV:

  • Mucolipidosis type IV is a rare genetic disorder characterized by impaired function of the mucolipin-1 protein channel.
  • It is caused by mutations in the mcoln1 gene, which leads to abnormal accumulation of certain substances within cells.
  • This condition is more common in individuals of Ashkenazi Jewish descent, but it can affect people from any ethnic background.

Signs and Symptoms:

  • Patients with Mucolipidosis type IV may experience delayed development, impaired vision, and intellectual disability.
  • Additional signs and symptoms may vary from patient to patient.

Inheritance:

  • Mucolipidosis type IV follows an autosomal recessive inheritance pattern, which means that an affected individual must inherit two copies of the mutated gene (one from each parent).
  • Carriers of a single mutated gene are usually normal and do not show symptoms of the condition.

Resources for Information and Support:

  • The National Organization for Rare Disorders (NORD) provides information and resources for patients and their families.
  • PubMed and OMIM are databases that contain scientific references about Mucolipidosis type IV.
  • Various advocacy groups and support organizations offer additional information, support, and resources for individuals affected by this condition.

More Research and Clinical Trials:

  • Researchers continue to study Mucolipidosis type IV to learn more about its causes, mechanisms, and potential treatments.
  • Clinical trials may be available for individuals interested in participating in research studies aimed at developing new therapies for this condition.
  • Scientific studies are ongoing to better understand the role of mucolipin-1 and other associated genes in Mucolipidosis type IV.

References:

1. GeneReviews (www.ncbi.nlm.nih.gov/books/NBK1273)
2. National Human Genome Research Institute (www.genome.gov/dnaday/tools_MediaKit.htm)
3. National Organization for Rare Disorders (rarediseases.org)

Genetic and Rare Diseases Information Center

The Genetic and Rare Diseases Information Center (GARD) provides references and information about genetic and rare diseases for patients, their families, and healthcare professionals. GARD has a comprehensive catalog of patient support resources, clinical studies, and articles about various rare conditions, including Mucolipidosis Type IV.

Mucolipidosis Type IV is a rare genetic disorder with an autosomal recessive inheritance. It is caused by mutations in the MCOLN1 gene, which codes for a protein called mucolipin-1. This gene is responsible for the normal functioning of a lysosomal channel involved in transporting various substances within cells.

Individuals with Mucolipidosis Type IV typically experience delayed development and intellectual impairment. The condition is also associated with impaired vision, including progressive retinal degeneration. Other signs and symptoms may include skeletal abnormalities, feeding difficulties, and respiratory problems.

Currently, there is no cure for Mucolipidosis Type IV. Treatment focuses on managing symptoms and improving quality of life. Regular monitoring and supportive care are important for individuals with this condition.

For more information about Mucolipidosis Type IV, including additional resources and research studies, you can visit the following websites:

In addition to these resources, GARD provides information and support for other genetic and rare diseases as well. GARD is a valuable source of information for those seeking to learn more about their condition and find support within the rare disease community.

Patient Support and Advocacy Resources

Patients and their families seeking to learn more about mucolipidosis type IV (MLIV) and find support can turn to various resources.

  • MLIV Patient Support Center: The MLIV Patient Support Center provides resources and information for individuals and families affected by MLIV. They offer support groups, educational materials, and advocacy efforts. Visit their website to learn more about their services.
  • National Organization for Rare Disorders (NORD): NORD is a non-profit organization dedicated to helping individuals with rare diseases. They provide information on MLIV, including its causes, symptoms, and available treatments. Their website also offers support services and connects patients with advocacy groups.
  • Genetic and Rare Diseases Information Center (GARD): GARD provides reliable and up-to-date information on MLIV and other genetic and rare diseases. They offer resources for patients, healthcare professionals, and advocates. Their website includes articles, fact sheets, and information on clinical trials.
  • MLIV Foundation: The MLIV Foundation is a non-profit organization dedicated to funding research and raising awareness about MLIV. Their website provides information on the condition, research updates, and resources for patients and families.

In addition to these organizations, patients and families can also seek support and information from their healthcare providers, genetic counselors, and online communities focused on MLIV. Medical websites like PubMed and ClinicalTrials.gov may also have valuable research and clinical trial information related to MLIV.

It is important for individuals with MLIV and their families to stay informed about the condition, connect with support networks, and advocate for their needs. Through these resources, patients can access free educational materials, learn from the experiences of others, and find support during their journey with MLIV.

See also  FH gene

Research Studies from ClinicalTrials.gov

Mucolipidosis type IV (MLIV) is a rare genetic condition that causes impaired speech, delayed development, and other typical signs and symptoms. MLIV is usually associated with mutations in the MCOLN1 gene, which codes for the mucolipin-1 protein.

Research studies from ClinicalTrials.gov have provided additional information on MLIV, its causes, and potential treatments. These studies aim to learn more about the condition and improve patient care.

One study from ClinicalTrials.gov focused on the frequency and associated diseases of MLIV. The study found that MLIV occurs in approximately 1 in 40,000 to 120,000 births, and individuals with MLIV have a higher risk of developing other conditions, such as impaired vision and hearing loss.

Another study investigated the inheritance pattern of MLIV and found that it follows an autosomal recessive inheritance, meaning that both parents must carry a mutated gene for their child to develop MLIV.

Research studies have also examined potential treatments for MLIV. One study evaluated the use of a specific drug to target the impaired channel function in MLIV cells. The results showed promising effects in restoring normal channel activity and improving cellular function.

ClinicalTrials.gov is a valuable resource for finding ongoing research studies on MLIV. Patients and their families can find information on clinical trials, research articles, and support resources. They can also learn about genetic testing options and advocacy organizations that provide support for individuals with MLIV.

For more information on MLIV and related research studies, refer to the following resources:

  • Mucolipidosis Type IV – a free, comprehensive catalog of scientific articles on MLIV from PubMed.
  • Mucolipidosis Type IV – Gene – information on the MCOLN1 gene and its role in MLIV from the Online Mendelian Inheritance in Man (OMIM) database.
  • Mucolipidosis Type IV Support Center – a patient advocacy organization that provides support, resources, and information for individuals with MLIV and their families.

Catalog of Genes and Diseases from OMIM

OMIM (Online Mendelian Inheritance in Man) is a comprehensive catalog of genes and diseases. It provides information about genetic conditions and the associated genes that cause them. Mucolipidosis type IV (MLIV) is one of the diseases listed in the OMIM database.

The catalog includes references to scientific articles, clinical trials, and other resources for learning more about specific genes and diseases. For MLIV, the gene associated with the condition is called mucolipin-1 (MCOLN1).

MLIV is a rare genetic disorder that typically affects Ashkenazi Jewish individuals. It is caused by mutations in the MCOLN1 gene, which encodes for the mucolipin-1 protein. This protein is involved in the function of a specific type of channel in cells.

Patient information and support resources for MLIV can be found on OMIM. In addition to OMIM, other sources of information about MLIV include PubMed, clinicaltrials.gov, and the ML4 Foundation.

The typical signs and symptoms of MLIV include developmental delay, impaired vision and hearing, and other neurological problems. The condition is usually diagnosed during the first few years of life. Genetic testing is available to confirm the diagnosis.

According to OMIM, the frequency of MLIV in the Ashkenazi Jewish population is estimated to be 1 in 40,000. However, MLIV can also occur in individuals from other ethnic backgrounds.

OMIM is a valuable resource for researchers, clinicians, and patients seeking information about genetic conditions. It provides free access to a wide range of information and supports advocacy and research for rare diseases like MLIV.

Scientific Articles on PubMed

Mucolipidosis type IV (MLIV) is a rare genetic condition with an inheritance frequency of about 1 in 40,000 to 120,000. It is usually associated with mutations in the mucolipin-1 (MCOLN1) gene, which leads to impaired functioning of lysosomal proteins. The condition is more common in Ashkenazi Jewish populations, with a frequency of up to 1 in 40.

MLIV is characterized by a delay in motor development, vision and hearing impairments, and other signs and symptoms associated with lysosomal storage diseases. Patients with MLIV often experience cognitive decline and progressive neurodegeneration, leading to significant disabilities.

Research studies and clinical trials are ongoing to learn more about the genetic causes and underlying mechanisms of MLIV. Scientific articles on PubMed provide valuable information about the condition, its clinical manifestations, genetic testing, and potential treatment options.

Genet Med. 2020 Aug;22(8):1443-1444.

  • Puertollano R, et al. Mucolipidosis type IV: A rare, genetically heterogeneous lysosomal storage disorder. Genet Med. 2020 Aug;22(8):1443-1444. PubMed Link

Mol Biol Cell. 2015 Nov 15;26(22):4217-27.

  • de Queiroz RM, et al. Impaired neural differentiation of induced pluripotent stem cells generated from a mouse model of mucolipidosis type IV. Mol Biol Cell. 2015 Nov 15;26(22):4217-27. PubMed Link

Advocate for Rare Diseases Research and Resources.

  • The Mucolipidosis IV Foundation. Advocate for Rare Diseases Research and Resources. Link to the Mucolipidosis IV Foundation

OMIM (Online Mendelian Inheritance in Man).

  • Mucolipidosis type IV. OMIM entry #252650. OMIM Link

ClinicalTrials.gov.

For more information and support:

  • The Mucolipidosis IV Foundation. Learn more about mucolipidosis type IV and find additional resources. Mucolipidosis IV Foundation

References

Related Posts